Bellevue Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Bellevue Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17K	Hold	4,627	–	–	﹤0.01%	148
2026 Q1	$14.2K	Sell	4,627 -294	-6%	-$1.14K	﹤0.01%	154
2025 Q4	$20.1K	Sell	4,921 -593	-11%	-$2.94K	﹤0.01%	176
2025 Q3	$26.9K	Hold	5,514	–	–	﹤0.01%	148
2025 Q2	$27.9K	Sell	5,514 -189,538	-97%	-$931K	﹤0.01%	141
2025 Q1	$1.03M	Sell	195,052 -182,754	-48%	-$1.33M	0.02%	107
2024 Q4	$2.55M	Sell	377,806 -15,075	-4%	-$101K	0.05%	105
2024 Q3	$2.59M	Sell	392,881 -32,929	-8%	-$236K	0.04%	104
2024 Q2	$3.19M	Buy	425,810 +561	+0.1%	+$4.89K	0.05%	104
2024 Q1	$4.24M	Buy	425,249 +250,692	+144%	+$2.79M	0.06%	99
2023 Q4	$1.72M	Buy	174,557 +472	+0.3%	+$3.37K	0.03%	109
2023 Q3	$1.33M	Buy	+174,085	New	+$1.74M	0.02%	120
2021 Q3	–	Sell	-20,000	Closed	-$730K	–	222
2021 Q2	$730K	Buy	+20,000	New	+$592K	0.01%	152

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bellevue Group's RXRX Position: Q2 2026 in Review

Bellevue Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 4,627 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #148.

Bellevue Group first reported a position in RXRX in Q2 2021 and has held it in 13 quarters since. The position peaked at $4.24M in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Bellevue Group held 4,627 shares of Recursion Pharmaceuticals worth $17K as of Q2 2026.
Bellevue Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #148 holding.
Bellevue Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 13 quarters since.
Bellevue Group's Recursion Pharmaceuticals position peaked at $4.24M in Q1 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.